



ABN: 15 129 742 409

Scale Back of Share Purchase Plan

Melbourne, Australia – 25 January 2017: dorsaVi Ltd (ASX: DVL (**dorsaVi** or **Company**)) is pleased to announce that dorsaVi's Share Purchase Plan (**SPP**) announced on 13 December 2016 has been very successful, with a strong response from eligible shareholders.

The SPP, which closed at 5.00pm on 19 January 2017, was capped at A\$1 million and formed part of a capital raising that also included a A\$7 million placement to sophisticated and professional investors (**Placement**). The offer price of the shares under the SPP was A\$0.46 per share, the same as the issue price under the Placement.

The Company advises that due to the strong support of eligible shareholders, all applicants who applied for an allotment of shares under the SPP will receive 53.98% of their application (rounded to the nearest whole number). Each applicant will receive a refund of excess application monies.

Following completion of the scale back, 2,173,850 new fully paid ordinary shares (**New Shares**) have been issued today.

The key dates follow below:

- the SPP allotment date is 25 January 2017;
- holding statements will be despatched on or around 27 January 2017; and
- refunds will be despatched to applicants on or around 2 February 2017.

The New Shares issued under the SPP will rank equally with the Company's existing ordinary shares.

About dorsaVi

dorsaVi (ASX:DVL) is an ASX company focused on developing innovative motion analysis device technologies for use in elite sports, occupational health and safety, and clinical applications. dorsaVi believes its wearable sensor technology enables – for the first time – many aspects of detailed human movement and position to be accurately captured, quantified and assessed outside a biomechanics lab, in both real-time and real situations for up to 24 hours.

Our technology has applications across three sectors:

- Clinical: ViMove is transforming the management of patients by providing an objective assessment, monitoring outside the clinic and immediate biofeedback. ViMove is currently used by medical and physiotherapy practices in Australia and the United Kingdom and is now available in the United States following FDA 510K clearance.

For personal use only

- **Elite Sports:** ViPerform is allowing coaches and medical teams managing elite athletes and teams to screen athletes and provide objective evidence for decisions on return to play, measure biomechanics and provide immediate biofeedback out on the field, tailor and track training programs and optimise technique and peak performance. ViPerform is being used by AFL and NRL clubs and the Australian Institute of Sport (AIS) in Australia. In the UK, Barclays Premier League (EPL), U.S. based sports clubs including the National Basketball Association (NBA) and the National Football League (NFL), and various Olympic teams and athletes internationally.
- **OHS:** We combine innovation, measurement and quality to reduce workplace incidents, costs, meet compliance and improve brand reputation. ViSafe enables employers to assess the risk of injury for employees as well as test the effectiveness of proposed changes to workplace design, equipment or methods based on objective evidence. ViSafe has been used by major corporations including Sodexo, London Underground, Vinci Construction, Crown Resorts, Caterpillar (US), Monash Health, Coles, Woolworths, Toll, Toyota, Orora (formerly Amcor), Crown and BHP Billiton. Australian Workplace Compliance delivers risk mitigation through compliance to OHS, Quality Management Systems, Company Policy and Process.

Further information is available at www.dorsavi.com.